News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioElectronics Corporation Announces Distribution Agreement With PD-Rx Pharmaceuticals, Inc. (PDRX.PK)


10/19/2005 5:13:12 PM

FREDERICK, Md., April 4 /PRNewswire-FirstCall/ -- BioElectronics Corporation (Pink Sheets: BIEL), a developer of advanced, disposable, therapeutic medical devices, announced that it has entered into an agreement with PD-Rx (Pink Sheets: PDRX) for PD-Rx to distribute ActiPatch(R) Therapy to physicians and healthcare providers that participate in the PD-Rx programs, according to Thomas J. O'Connor, Executive Vice President and COO of BioElectronics.

O'Connor continued, "We are pleased to partner with PD-Rx to make the ActiPatch product line available to the over 4000 providers that participate in the PD-Rx programs. PD-Rx has a great track record with new products and an excellent reputation for outstanding customer service. This is another example of how BioElectronics is aggressively pursuing partnerships that will make ActiPatch Therapy available on a wide scale basis."

Jack McCall, Executive Vice President and COO of PD-Rx, added, "PD-Rx is excited about this new partnership. We believe the ActiPatch product line will be a big hit with our customers and we look forward to working closely with the BioElectronics team to provide high service levels to providers using the products."

BioElectronics Corporation is a developer and marketer of advanced, inexpensive, disposable, drug-free, medical devices cleared by the US FDA, the European Union and the Canadian regulatory authorities. ActiPatch(R) Therapy is a dermal patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a few dollars a day. The patch delivery system and the Company's patented technology provides an inexpensive, self- administered equivalent of the operator-administered pulsed electromagnetic energy therapy used extensively world-wide to reduce swelling, relieve pain and enhance the healing of post-surgical incisions, chronic wounds (bedsores) and orthopedic conditions. For more information, visit http://www.bioelectronicscorp.com/ .

PD-Rx ( http://www.pdrx.com/ ) offers pharmaceutical and management strategies to the healthcare industry. PD-Rx's management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and repackager, PD-Rx offers a full spectrum of medications and specialized services. PD-Rx's goal is to develop a matrix of cost containment tools and products that it can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. PD-Rx provides proprietary products and prepackaged medications that are viewed by patient, insurance payers, and healthcare providers as a progressive and responsive practice.

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the Company has no control.

For further information, contact: Andrew J. Whelan, President & CEO Thomas O'Connor, EVP & COO 301/874-0326 info@bioelectronicscorp.com

BioElectronics Corporation

CONTACT: Andrew J. Whelan, President & CEO, or, Thomas O'Connor, EVP &COO, both of BioElectronics Corporation, +1-301-874-0326,info@bioelectronicscorp.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES